Category Archives: IPR

European FTA pushes for tougher IPR rules under ongoing trade talks with India

Switzerland proposed that India agree to broader patentable principles, as per a leaked note on the proposed Intellectual Property Rights chapter of the talks   The leaked note followed a telephone conversation commerce minister Sitharaman and Swiss minister for economic … Continue reading

Posted in Data Exclusivity, EFTA-India FTA, Evergreening, IPR, Patent, Uncategorized | Leave a comment

16-nation RCEP talks resume in wake of TPP’s demise

By Eric Johnston, Japan Times KOBE – The 16-nation Regional Comprehensive Economic Partnership, a multilateral agreement that would cover half the world’s population, has reached a major turning point, delegates said Monday at the start of five days of negotiations. … Continue reading

Posted in IPR, Regional Comprehensive Economic Partnership, TPP, Uncategorized | Leave a comment

RCEP and Health: This Kind of ‘Progress’ is Not What India and the World Need

Source: The Wire Concerns remain over the impact of RCEP negotiations on public health and access to medicines Negotiators from 16 countries are meeting in Kobe, Japan on Monday to begin the 17th round of negotiations of the Regional Comprehensive Economic … Continue reading

Posted in Data Exclusivity, Investor state dispute, IPR, Patent, Patent Term Extension, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Civil society, patient groups call on Japan and South Korea to withdraw harmful proposals from RCEP negotiations

By Ramesh Shankar, http://www.pharmabiz.com | February 24, 2017 As 16 countries negotiating the Regional Comprehensive Economic Partnership (RCEP) agreement meet next week in Kobe, Japan, for the seventeenth round of negotiations, civil society and patient groups, including the international medical humanitarian … Continue reading

Posted in Data Exclusivity, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TPP, Uncategorized | Leave a comment

India on stronger footing to resist IPR framework at RCEP

Stiff negotiations on goods, services expected at Kobe meet By Amiti Sen, Hindu BusinessLine | FEBRUARY 23, 2017 India will be on a stronger wicket to oppose the stringent IPR framework being pushed by some members at the next negotiating round … Continue reading

Posted in IPR, Regional Comprehensive Economic Partnership, TPP, Uncategorized | Leave a comment

Indian pharma at odds with US trade group over USTR Priority Watch List

The tug of war continues. Even as the Indian Pharmaceutical Alliance, the domestic drug industry lobby group, has appealed to the US Trade Representative to remove India from its Priority Watch List – the latter includes countries that are alleged … Continue reading

Posted in IP Rights, IPR, IPR policy, Special 301 report, Uncategorized, USTR 301 report | Leave a comment

Indian pharma industry fears tougher US stance on IP

Prices of patented drugs are lower in Canada, United Kingdom and Australia in comparison to the US By Aneesh Phadnis & Reuters| Published: Business Standard | february 1, 2017 Indian pharma industry is fearing a tougher US government stance on intellectual … Continue reading

Posted in Generics, IPR, Uncategorized, US pressure on India | Leave a comment